Ultime notizie per Fortrea Holdings (NASDAQ:FTRE) Azioni

Fortrea Holdings

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

News

Pre-Market Outlook

Markets

Trading Ideas

BEKE

FTRE

MNDY

Scopri i cinque titoli chiave da seguire nel pre-market di oggi, 12 agosto 2024, con focus su risultati e previsioni.

Pre-market: 5 titoli da monitorare oggi, 12 agosto 2024

Fortrea Holdings Inc

AMN Healthcare Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>) sees Q4 sales of $685.000 million-705.000 million vs $667.95 million estimate.

Guidance

AMN Healthcare Services Sees Q4 Sales $685.000M-705.000M vs $667.95M Est

The One Group Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $0.01 by 3100 percent. The company reported quarterly sales of $193.975 million which missed the analyst consensus estimate of $215.463 million by 9.97 percent. This is a 152.30 percent increase over sales of $76.884 million the same period last year.

Earnings

Earnings Misses

STKS

The One Group Hospitality Q3 2024 Adj. EPS $(0.30) Misses $0.01 Estimate, Sales $193.975M Miss $215.463M Estimate

Saul Centers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFS#NYSE">BFS</a>) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.43 by 11.63 percent. The company reported quarterly sales of $67.30 million which beat the analyst consensus estimate of $65.78 million by 2.31 percent. This is a 5.54 percent increase over sales of $63.77 million the same period last year.

Earnings Beats

Saul Centers Q3 2024 GAAP EPS $0.48 Beats $0.43 Estimate, Sales $67.30M Beat $65.78M Estimate

WIIM

BILL

BILL Holdings shares are trading higher after the company reported better-than-expected Q1 financial results and issued FY25 guidance above estimates

LivePerson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPSN#NASDAQ">LPSN</a>) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.22) by 45.45 percent. This is a 52.94 percent increase over losses of $(0.68) per share from the same period last year. The company reported quarterly sales of $74.244 million which beat the analyst consensus estimate of $71.127 million by 4.38 percent. This is a 26.73 percent decrease over sales of $101.332 million the same period last year.

LPSN

LivePerson Q3 2024 GAAP EPS $(0.32) Misses $(0.22) Estimate, Sales $74.244M Beat $71.127M Estimate

ADEA

Adeia Files Multiple Patent Infringement Lawsuits Against Disney, Hulu, And ESPN In U.S. And Europe; Legal Actions Initiated In Delaware And Across European Courts

NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.30) by 100 percent. This is a 95.42 percent increase over losses of $(13.11) per share from the same period last year. The company reported quarterly sales of $2.44 million which missed the analyst consensus estimate of $2.62 million by 6.94 percent. This is a 1.61 percent decrease over sales of $2.48 million the same period last year.

NovaBay Pharmaceuticals Q3 EPS $(0.60) Misses $(0.30) Estimate, Sales $2.44M Miss $2.62M Estimate

Universal Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UEIC#NASDAQ">UEIC</a>) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.12 by 16.67 percent. The company reported quarterly sales of $102.073 million which missed the analyst consensus estimate of $102.718 million by 0.63 percent. This is a 4.69 percent decrease over sales of $107.095 million the same period last year.

UEIC

Universal Electronics Q3 2024 Adj. EPS $0.10 Misses $0.12 Estimate, Sales $102.073M Miss $102.718M Estimate

BNED

Barnes & Noble Education Sees Prelim Q2 First Day Program Revenue $235M

Metallus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTUS#NYSE">MTUS</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.02) by 350 percent. The company reported quarterly sales of $227.200 million which missed the analyst consensus estimate of $274.367 million by 17.19 percent. This is a 35.86 percent decrease over sales of $354.200 million the same period last year.

MTUS

Metallus Q3 2024 Adj. EPS $(0.09) Misses $(0.02) Estimate, Sales $227.200M Miss $274.367M Estimate

ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.01) by 300 percent.

LOGC

ContextLogic Q3 2024 GAAP EPS $(0.04) Misses $(0.01) Estimate

Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(0.98) by 3.06 percent. This is a 35.71 percent decrease over losses of $(0.70) per share from the same period last year.

PLRX

Pliant Therapeutics Q3 EPS $(0.95) Beats $(0.98) Estimate

ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 33.33 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $36.325 million which beat the analyst consensus estimate of $35.609 million by 2.01 percent. This is a 7.39 percent decrease over sales of $39.222 million the same period last year.

ONTF

ON24 Q3 2024 Adj. EPS $0.02 Beats $0.00 Estimate, Sales $36.325M Beat $35.609M Estimate

Skillz (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKLZ#NYSE">SKLZ</a>) reported quarterly losses of $(1.20) per share which missed the analyst consensus estimate of $(1.11) by 8.11 percent. The company reported quarterly sales of $24.564 million which missed the analyst consensus estimate of $26.657 million by 7.85 percent. This is a 32.57 percent decrease over sales of $36.427 million the same period last year.

SKLZ

Skillz Q3 2024 GAAP EPS $(1.20) Misses $(1.11) Estimate, Sales $24.564M Miss $26.657M Estimate

Management

Eventbrite Appoints Anand Gandhi As CFO, Effective Nov. 19; Lanny Baker Shifts Focus To COO Role To Drive Operational Excellence And Growth

Transcontinental Realty Q3 EPS $0.20 Down From $0.52 YoY, Sales $11.607M Down From $12.525M YoY

Olo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLO#NYSE">OLO</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.05 by 20 percent. This is a 50 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $71.853 million which beat the analyst consensus estimate of $70.940 million by 1.29 percent. This is a 24.33 percent increase over sales of $57.794 million the same period last year.

Olo Q3 2024 Adj. EPS $0.06 Beats $0.05 Estimate, Sales $71.853M Beat $70.940M Estimate

Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.08) by 25 percent. The company reported quarterly sales of $10.867 million which missed the analyst consensus estimate of $12.091 million by 10.12 percent. This is a 36.78 percent decrease over sales of $17.190 million the same period last year.

TACT

Transact Technologies Q3 2024 GAAP EPS $(0.06) Beats $(0.08) Estimate, Sales $10.867M Miss $12.091M Estimate

UPST

Upstart Holdings shares are trading higher after the company reported better-than-expected Q3 financial results.

Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $(0.41) by 151.22 percent. This is a 160 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $71.75 million which beat the analyst consensus estimate of $16.27 million by 340.98 percent. This is a 667.19 percent increase over sales of $9.35 million the same period last year.

PSTX

Poseida Therapeutics Q3 EPS $0.21 Beats $(0.41) Estimate, Sales $71.75M Beat $16.27M Estimate

Jana Partners top buys and sells in Q2

Starboard Value reduces stake in GoDaddy, increases Salesforce, others in Q2

Diamond Hill Small-Mid Cap Fund Q2 2024 Market Commentary

Tracking Seth Klarman's Baupost Group Holdings - Q2 2024 Update

Warning: FTRE is at high risk of performing badly

Medpace, Fortrea cut as Jefferies reviews CROs amid biotech headwinds

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fortrea Holdings Inc. (FTRE – Research Report) and...

Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE) and PDS Biotechnology (PDSB)

Fortrea gains after activist investor Corvex discloses stake

Corvex Management has acquired a stake in Fortrea Holdings (FTRE), the clinical trials business that was spun out off Labcorp (LH), Bloomberg's Cry...

Activist Corvex acquires stake in Fortrea Holdings, Bloomberg reports

ALIT

CLVT

COOP

CPRI

DHIL

ENOV

FRPT

FYBR

GDDY

GDHLF

GNRC

GOOG

GOOGL

ICLR

JAZZ

LBTYA

LBTYB

LBTYK

LSXMA

LSXMB

LSXMK

MEDP

NWSA

PDSB

QDEL

SANM

SOLV

TBPH

TRMB

VRSN

VSAT

WOLF

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE

FTRE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fortrea Holdings Inc. and Encourages Investors to Contact the Firm

Legal

Fortrea Announces Date for Third Quarter 2024 Financial Results and Conference Call

Fortrea Releases Inaugural Corporate Social Responsibility Report

Agilent Technologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Fortrea Holdings

Notizie

Ultime notizie per Fortrea Holdings (NASDAQ:FTRE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO